Get the Daily Brief
Latest Biotech News
Oncology – immunotherapy and trial results
New Phase 3 data show that adding perioperative immunotherapy can extend outcomes for resectable lung cancer. In final results from the Phase 3 IMpower030 study, patients with resectable stage...
Oncology – precision imaging for treatment guidance
Researchers are moving toward imaging approaches that can verify whether immunotherapy drugs reach tumors and engage targets. A study in the British Journal of Cancer evaluated PET imaging...
Biotech finance and pipeline risk
SELLAS Life Sciences shares fell sharply without any disclosed failed clinical event in the public record, highlighting the market’s sensitivity to timing around binary readouts. The company’s...
Clinical development – oncology drug combinations
A new early-phase study is testing whether adding glutamine can improve outcomes in advanced pancreatic ductal adenocarcinoma. In the open-label GlutaPanc Phase 1 trial, investigators evaluated...
Biotech manufacturing and capacity deals
Samsung Biologics announced a long-term manufacturing agreement worth $262 million with a European pharma company, with production commitments extending through 2033. The deal will be executed at...
Clinical development – gene therapy in SMA
A real-world analysis is reinforcing gene therapy durability in severe infant spinal muscular atrophy. Researchers drew on Italy’s national registry to assess two-year outcomes following a single...
Oncology – investigational combination with checkpoint blockade
Solstice is pushing a next-generation CTLA-4 strategy into the neoadjuvant setting with new backing. In a deal described as CAP-led syndicate support for a NewCo, the transaction includes a $225...
Health technology and diagnostics
Researchers are developing smarter tools for pathology-driven decision support, aiming to reduce manual interpretive burden in oncology. A new AI system reads whole pathology slides and can answer...
Virology and infectious disease
An emerging SARS-CoV-2 sublineage is coming under additional characterization as surveillance highlights its structural and functional features. Researchers analyzed the RE.2.2 lineage, described...
FDA action and regulatory milestones
The FDA approved Scholar Rock’s Isembyld (myostatin inhibitor, used with SMN2-targeted therapy) for spinal muscular atrophy muscle loss in adults and children aged 2 and older, based on late-stage...
Late-stage oncology readouts and translational imaging guidance
Final results from the Phase 3 IMpower030 trial showed that adding atezolizumab to platinum chemotherapy before and after surgery more than doubled event-free survival in patients with resectable...
Clinical progress and expansion in rare disease gene therapy and blood cancers
New registry analysis suggests gene therapy can deliver durable, two-year gains in infants with severe spinal muscular atrophy, adding to evidence that early-life delivery may translate into...
Biotech financing and commercialization partnerships
Transcenta Therapeutics and WuXi Biologics announced a licensing collaboration to accelerate commercialization of Transcenta’s intensified continuous bioprocessing (HiCB) technology and ExcelPro...
High-impact clinical development: trial reads, study timing, and risk
SELLAS Life Sciences shares fell after traders reduced risk ahead of two binary clinical milestones, including REGAL’s Phase 3 data readout for galinpepimut-S (GPS) maintenance in AML patients in...
New oncology mechanism biology with translational implications
A study reported in Nature Cancer found pancreatic tumors can evade ferroptosis and resist chemotherapy by using a previously identified protein modification strategy. The work connects tumor...
Advanced diagnostics and biomarkers for precision oncology
A real-world breast cancer imaging and biomarker development theme emerged from an analysis of post-therapy esophageal tissue showing that cancer treatments can alter the landscape of somatic...
Neuro and rare disease therapeutics: gene delivery and functional recovery
A two-year, real-world outcome analysis reported durable gains in infants with severe SMA following early gene therapy, reinforcing the translational signal that timing and dosing can preserve...
AI-driven healthcare tooling with clinical relevance
An automated system described in Japan demonstrated it can detect pneumothorax in newborns with high accuracy, addressing a clinical blind spot where subtle imaging findings are easy to miss. The...
Massive financing and commercialization runway for gene therapy
Encoded Therapeutics secured a $275 million Series F to push ETX101, its lead genetic medicine for SCN1A-positive Dravet syndrome, into clinical trials. The financing funds registration-directed...
FDA approvals – SMA muscle loss therapy
FDA has approved Scholar Rock’s myostatin-inhibition therapy Isembyld (for adults and children 2 years and older) for spinal muscular atrophy patients who are already receiving SMN2-targeting...